Diverging gain-of-function mechanisms of two novel KRAS mutations associated with Noonan and cardio-facio-cutaneous syndromes.
Activating somatic and germline mutations of closely related RAS genes (H, K, N) have been found in various types of cancer and in patients with developmental disorders, respectively. The involvement of the RAS signalling pathways in developmental disorders has recently emerged as one of the most important drivers in RAS research. In the present study, we investigated the biochemical and cell biological properties of two novel missense KRAS mutations (Y71H and K147E). Both mutations affect residues that are highly conserved within the RAS family. KRAS(Y71H) showed no clear differences to KRAS(wt), except for an increased binding affinity for its major effector, the RAF1 kinase. Consistent with this finding, even though we detected similar levels of active KRAS(Y71H) when compared with wild-type protein, we observed an increased activation of MEK1/2, irrespective of the stimulation conditions. In contrast, KRAS(K147E) exhibited a tremendous increase in nucleotide dissociation generating a self-activating RAS protein that can act independently of upstream signals. As a consequence, levels of active KRAS(K147E) were strongly increased regardless of serum stimulation and similar to the oncogenic KRAS(G12V). In spite of this, KRAS(K147E) downstream signalling did not reach the level triggered by oncogenic KRAS(G12V), especially because KRAS(K147E) was downregulated by RASGAP and moreover exhibited a 2-fold lower affinity for RAF kinase. Here, our findings clearly emphasize that individual RAS mutations, despite being associated with comparable phenotypes of developmental disorders in patients, can cause remarkably diverse biochemical effects with a common outcome, namely a rather moderate gain-of-function.
Institute of Biochemistry & Molecular Biology II, Heinrich-Heine University, Düsseldorf 40225, Germany.
Ion C
IC
Cirstea
Lothar
L
Gremer
Radovan
R
Dvorsky
Si-Cai
SC
Zhang
Roland P
RP
Piekorz
Martin
M
Zenker
Mohammad Reza
MR
Ahmadian
D002460:Cell Line; D004476:Ectodermal Dysplasia / Q000235:genetics* / Q000378:metabolism*; D019066:Facies; D005183:Failure to Thrive / Q000235:genetics* / Q000378:metabolism*; D006330:Heart Defects, Congenital / Q000235:genetics* / Q000378:metabolism*; D006801:Humans; D009154:Mutation; D009634:Noonan Syndrome / Q000235:genetics* / Q000378:metabolism*; D011485:Protein Binding; D011487:Protein Conformation; D055550:Protein Stability; D015398:Signal Transduction; D018631:ras Proteins / Q000737:chemistry / Q000235:genetics* / Q000378:metabolism*
D018631:ras Proteins